Lee W Jones1, Qi Liu2, Gregory T Armstrong2, Kirsten K Ness2, Yutaka Yasui2, Katie Devine2, Emily Tonorezos2, Luisa Soares-Miranda2, Charles A Sklar2, Pamela S Douglas2, Leslie L Robison2, Kevin C Oeffinger2. 1. Lee W. Jones, Emily Tonorezos, Charles A. Sklar, Kevin C. Oeffinger, the Memorial Sloan Kettering Cancer Center, New York, NY; Qi Liu, Yutaka Yasui, University of Alberta, Edmonton, Alberta, Canada; Gregory T. Armstrong, Kirsten K. Ness, Leslie L. Robison, St. Jude Children's Research Hospital, Memphis, TN; Katie Devine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Luisa Soares-Miranda, Research Center in Physical Activity Health and Leisure, University of Porto, Porto, Portugal; Pamela S. Douglas, Duke University Medical Center, Durham, NC. jonesl3@mskcc.org. 2. Lee W. Jones, Emily Tonorezos, Charles A. Sklar, Kevin C. Oeffinger, the Memorial Sloan Kettering Cancer Center, New York, NY; Qi Liu, Yutaka Yasui, University of Alberta, Edmonton, Alberta, Canada; Gregory T. Armstrong, Kirsten K. Ness, Leslie L. Robison, St. Jude Children's Research Hospital, Memphis, TN; Katie Devine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ; Luisa Soares-Miranda, Research Center in Physical Activity Health and Leisure, University of Porto, Porto, Portugal; Pamela S. Douglas, Duke University Medical Center, Durham, NC.
Abstract
PURPOSE: Survivors of Hodgkin lymphoma (HL) are at increased risk of treatment-related cardiovascular (CV) events; whether exercise modifies this risk is unknown. METHODS: Survivors of HL (n = 1,187; median age, 31.2 years) completed a questionnaire evaluating vigorous-intensity exercise behavior. CV events were collected in follow-up questionnaires and graded according to Common Terminology Criteria for Adverse Events (version 4.03). The primary end point was incidence of any major (grade 3 to 5) CV event. Poisson regression analyses were used to estimate the association between exercise exposure (metabolic equivalent [MET] hours/week(-1)) and risk of major CV events after adjustment for clinical covariates and cancer treatment. RESULTS: Median follow-up was 11.9 years (range, 1.7 to 14.3 years). Cumulative incidence of any CV event was 12.2% at 10 years for survivors reporting 0 MET hours/week(-1) compared with 5.2% for those reporting ≥ 9 MET hours/week(-1). In multivariable analyses, the incidence of any CV event decreased across increasing MET categories (Ptrend = .002). Compared with survivors reporting 0 MET hours/week(-1), the adjusted rate ratio for any CV event was 0.87 (95% CI, 0.56 to 1.34) for 3 to 6 MET hours/week(-1), 0.45 (95% CI, 0.26 to 0.80) for 9 to 12 MET hours/week(-1), and 0.47 (95% CI, 0.23 to 0.95) for 15 to 21 MET hours/week(-1). Adherence to national vigorous intensity exercise guidelines (ie, ≥ 9 MET hours/week(-1)) was associated with a 51% reduction in the risk of any CV event in comparison with not meeting the guidelines (P = .002). CONCLUSION: Vigorous exercise was associated with a lower risk of CV events in a dose-dependent manner independent of CV risk profile and treatment in survivors of HL.
PURPOSE: Survivors of Hodgkin lymphoma (HL) are at increased risk of treatment-related cardiovascular (CV) events; whether exercise modifies this risk is unknown. METHODS: Survivors of HL (n = 1,187; median age, 31.2 years) completed a questionnaire evaluating vigorous-intensity exercise behavior. CV events were collected in follow-up questionnaires and graded according to Common Terminology Criteria for Adverse Events (version 4.03). The primary end point was incidence of any major (grade 3 to 5) CV event. Poisson regression analyses were used to estimate the association between exercise exposure (metabolic equivalent [MET] hours/week(-1)) and risk of major CV events after adjustment for clinical covariates and cancer treatment. RESULTS: Median follow-up was 11.9 years (range, 1.7 to 14.3 years). Cumulative incidence of any CV event was 12.2% at 10 years for survivors reporting 0 MET hours/week(-1) compared with 5.2% for those reporting ≥ 9 MET hours/week(-1). In multivariable analyses, the incidence of any CV event decreased across increasing MET categories (Ptrend = .002). Compared with survivors reporting 0 MET hours/week(-1), the adjusted rate ratio for any CV event was 0.87 (95% CI, 0.56 to 1.34) for 3 to 6 MET hours/week(-1), 0.45 (95% CI, 0.26 to 0.80) for 9 to 12 MET hours/week(-1), and 0.47 (95% CI, 0.23 to 0.95) for 15 to 21 MET hours/week(-1). Adherence to national vigorous intensity exercise guidelines (ie, ≥ 9 MET hours/week(-1)) was associated with a 51% reduction in the risk of any CV event in comparison with not meeting the guidelines (P = .002). CONCLUSION: Vigorous exercise was associated with a lower risk of CV events in a dose-dependent manner independent of CV risk profile and treatment in survivors of HL.
Authors: Philip J Troped; Jean L Wiecha; Maren S Fragala; Charles E Matthews; Daniel M Finkelstein; Juhee Kim; Karen E Peterson Journal: Med Sci Sports Exerc Date: 2007-03 Impact factor: 5.411
Authors: Wendy M Leisenring; Ann C Mertens; Gregory T Armstrong; Marilyn A Stovall; Joseph P Neglia; Jennifer Q Lanctot; John D Boice; John A Whitton; Yutaka Yasui Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Laura K Stewart; Michael G Flynn; Wayne W Campbell; Bruce A Craig; J Paul Robinson; Kyle L Timmerman; Brian K McFarlin; Paul M Coen; Erin Talbert Journal: Med Sci Sports Exerc Date: 2007-10 Impact factor: 5.411
Authors: Webb A Smith; Kirsten K Ness; Vijaya Joshi; Melissa M Hudson; Leslie L Robison; Daniel M Green Journal: Pediatr Blood Cancer Date: 2013-11-06 Impact factor: 3.167
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Daniel A Mulrooney; Mark W Yeazel; Toana Kawashima; Ann C Mertens; Pauline Mitby; Marilyn Stovall; Sarah S Donaldson; Daniel M Green; Charles A Sklar; Leslie L Robison; Wendy M Leisenring Journal: BMJ Date: 2009-12-08
Authors: Emily S Tonorezos; Melissa M Hudson; Angela B Edgar; Leontien C Kremer; Charles A Sklar; W Hamish B Wallace; Kevin C Oeffinger Journal: Lancet Diabetes Endocrinol Date: 2015-04-12 Impact factor: 32.069
Authors: Kasey J Leger; K Scott Baker; Kara L Cushing-Haugen; Mary E D Flowers; Wendy M Leisenring; Paul J Martin; Jason A Mendoza; Kerryn W Reding; Karen L Syrjala; Stephanie J Lee; Eric J Chow Journal: Cancer Date: 2018-01-09 Impact factor: 6.860
Authors: Kirsten K Ness; Gregory T Armstrong; Mondira Kundu; Carmen L Wilson; Tamara Tchkonia; James L Kirkland Journal: Cancer Date: 2014-12-19 Impact factor: 6.860
Authors: Katie A Devine; Ann C Mertens; John A Whitton; Carmen L Wilson; Kirsten K Ness; Jordan Gilleland Marchak; Wendy Leisenring; Kevin C Oeffinger; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: Psychooncology Date: 2017-08-31 Impact factor: 3.894